Aprutumab, {a specific ADC, provides {a potential breakthrough in combating cancers driven by FGFR2 mutations. This targeted therapy functions by selectively inhibiting FGFR2, a tyrosine kinase often amplified in aggressive types of breast cancer. Early clinical trials demonstrated {encouraging data, including tumor shrinkage and improved prognosis